Actively Recruiting
Tranexamic Acid During Colonic Endoscopic Resection Procedures
Led by Assaf-Harofeh Medical Center · Updated on 2026-01-13
200
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.
CONDITIONS
Official Title
Tranexamic Acid During Colonic Endoscopic Resection Procedures
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in the colon presenting to our tertiary academic center.
- Age > 18 years
You will not qualify if you...
- Patients with histories of allergic reactions to TXA
- History of seizures
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shamir Medical Center
Be’er Ya‘aqov, Israel, 70300
Actively Recruiting
Research Team
A
Anton Bermont, MD
CONTACT
S
Sergei Vosko, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here